Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893616 | 0.99 | ALOX5 (0.32) | ALOX5MAPT | |
| SCHEMBL12583177 | 0.93 | GPR84 (0.32) | ALOX5 | |
| SCHEMBL12583392 | 0.88 | GPR84 (0.32) | ALOX5MAPT | |
| SCHEMBL12582994 | 0.87 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL12583185 | 0.86 | ALOX5 (0.34) | ALOX5MAPT | |
| SCHEMBL12583086 | 0.86 | GPR84 (0.42) | ALOX5MAPT | |
| SCHEMBL14498205 | 0.86 | ALOX5 (0.40) | ALOX5MAPT | |
| SCHEMBL12583114 | 0.85 | ALOX5 (0.38) | ALOX5MAPT | |
| SCHEMBL12583435 | 0.85 | ADORA2A (0.34) | ALOX5MAPT | |
| Bromide SCHEMBL6117953 | 0.84 | CNR2 (0.32) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124469-A1 | PROCESS FOR PRODUCING 1-ARYLIMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID DERIVATIVE | Kaneka Corporation (JP) | 2017-02-01 | — | — | EP | claimed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240239816-A1 | BORONO-PHENYLALANINE DERIVATIVE | STELLA PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4361159-A1 | BORONO-PHENYLALANINE DERIVATIVE | Stella Pharma Corporation (JP) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022270143-A1 | BORONO-PHENYLALANINE DERIVATIVE | ステラファーマ株式会社 | 2022-12-29 | — | — | WO | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-3333165-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-3124469-A1 | PROCESS FOR PRODUCING 1-ARYLIMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID DERIVATIVE | Kaneka Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-8742162-B2 | Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2465845-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ESTER | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120130116-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2010070593-A2 | MALONATE ESTERS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | ALOX5 2450/4885MAPT 3224/4885 |
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | ALOX5 753/4885MAPT 3175/4885 |
| US-20120130116-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ESTER | ALAD, AMD1, ALDH7A1 | ALOX5 514/4885MAPT 4585/4885 |
| US-20240239816-A1 | BORONO-PHENYLALANINE DERIVATIVE | SLC7A1, SLC1A5, LATS2 | ALOX5 3005/4885MAPT 874/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ALOX5 1993/4885MAPT 3196/4885 |
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | ALOX5 715/4885MAPT 3011/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ALOX5 2450/4885MAPT 3224/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | ALOX5 2205/4885MAPT 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.